Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2015 (2015), Article ID 379568, 8 pages
http://dx.doi.org/10.1155/2015/379568
Research Article

The Clinical and Pathological Significance of Nectin-2 and DDX3 Expression in Pancreatic Ductal Adenocarcinomas

1Research Laboratory of Hepatobiliary Diseases, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China
2Department of Pathology, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China
3Department of Pathology, Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China

Received 26 March 2015; Revised 17 May 2015; Accepted 4 June 2015

Academic Editor: Stamatios Theocharis

Copyright © 2015 Shan Liang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M. J. Thun, “Cancer statistics, 2009,” CA: A Cancer Journal for Clinicians, vol. 59, no. 4, pp. 225–249, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Siegel, J. Ma, Z. Zou, and A. Jemal, “Cancer statistics, 2014,” CA: Cancer Journal for Clinicians, vol. 64, no. 1, pp. 9–29, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. K. F. D. Kuhlmann, S. M. M. de Castro, J. G. Wesseling et al., “Surgical treatment of pancreatic adenocarcinoma: actual survival and prognostic factors in 343 patients,” European Journal of Cancer, vol. 40, no. 4, pp. 549–558, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Winner, S. L. Goff, and J. A. Chabot, “Neoadjuvant therapy for Non-metastatic Pancreatic Ductal Adenocarcinoma,” Seminars in Oncology, vol. 42, no. 1, pp. 86–97, 2015. View at Publisher · View at Google Scholar
  5. D. D. Von Hoff, T. Ervin, F. P. Arena et al., “Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine,” The New England Journal of Medicine, vol. 369, no. 18, pp. 1691–1703, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. Takai, K. Irie, K. Shimizu, T. Sakisaka, and W. Ikeda, “Nectins and nectin-like molecules: roles in cell adhesion, migration, and polarization,” Cancer Science, vol. 94, no. 8, pp. 655–667, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. Takai, W. Ikeda, H. Ogita, and Y. Rikitake, “The immunoglobulin-like cell adhesion molecule nectin and its associated protein afadin,” Annual Review of Cell and Developmental Biology, vol. 24, pp. 309–342, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Castriconi, A. Dondero, M. V. Corrias et al., “Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction,” Cancer Research, vol. 64, no. 24, pp. 9180–9184, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Fuchs and M. Colonna, “The role of NK cell recognition of nectin and nectin-like proteins in tumor immunosurveillance,” Seminars in Cancer Biology, vol. 16, no. 5, pp. 359–366, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Tomasec, E. C. Y. Wang, A. J. Davison et al., “Downregulation of natural killer cell-activating ligand CD155 by human cytomegalovirus UL141,” Nature Immunology, vol. 6, no. 2, pp. 181–188, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. M. El-Sherbiny, J. L. Meade, T. D. Holmes et al., “The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells,” Cancer Research, vol. 67, no. 18, pp. 8444–8449, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. B. Sanchez-Correa, I. Gayoso, J. M. Bergua et al., “Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients,” Immunology and Cell Biology, vol. 90, no. 1, pp. 109–115, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. D. H. J. Verhoeven, A. S. K. de Hooge, E. C. K. Mooiman et al., “NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways,” Molecular Immunology, vol. 45, no. 15, pp. 3917–3925, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. T. A. Martin, J. Lane, G. M. Harrison, and W. G. Jiang, “The expression of the nectin complex in human breast cancer and the role of Nectin-3 in the control of tight junctions during metastasis,” PLoS ONE, vol. 8, no. 12, Article ID e82696, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Oshima, S. Sato, J. Kato et al., “Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers,” Molecular Cancer, vol. 12, no. 1, article 60, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. X. Miao, Z.-L. Yang, L. Xiong et al., “Nectin-2 and DDX3 are biomarkers for metastasis and poor prognosis of squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladder,” International Journal of Clinical & Experimental Pathology, vol. 6, no. 2, pp. 179–190, 2013. View at Google Scholar · View at Scopus
  17. G. Guzman, S. Oh, D. Shukla, and T. Valyi-Nagy, “Nectin-1 expression in the normal and neoplastic human uterine cervix,” Archives of Pathology and Laboratory Medicine, vol. 130, no. 8, pp. 1193–1195, 2006. View at Google Scholar · View at Scopus
  18. P. Linder, “Yeast RNA helicases of the DEAD-box family involved in translation initiation,” Biology of the Cell, vol. 95, no. 3-4, pp. 157–167, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Rosner and B. Rinkevich, “The DDX3 subfamily of the DEAD box helicases: divergent roles as unveiled by studying different organisms and in vitro assays,” Current Medicinal Chemistry, vol. 14, no. 23, pp. 2517–2525, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Schröder, “Human DEAD-box protein 3 has multiple functions in gene regulation and cell cycle control and is a prime target for viral manipulation,” Biochemical Pharmacology, vol. 79, no. 3, pp. 297–306, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. Y.-J. Choi and S.-G. J. Lee, “The DEAD-box RNA helicase DDX3 interacts with DDX5, co-localizes with it in the cytoplasm during the G2/M phase of the cycle, and affects its shuttling during mrnp export,” Journal of Cellular Biochemistry, vol. 113, no. 3, pp. 985–996, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. C.-H. Chao, C.-M. Chen, P.-L. Cheng, J.-W. Shih, A.-P. Tsou, and Y.-H. W. Lee, “DDX3, a DEAD box RNA helicase with tumor growth-suppressive property and transcriptional regulation activity of the p21waf1/cip1 promoter, is a candidate tumor suppressor,” Cancer Research, vol. 66, no. 13, pp. 6579–6588, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. P.-C. Chang, C.-W. Chi, G.-Y. Chau et al., “DDX3, a DEAD box RNA helicase, is deregulated in hepatitis virus-associated hepatocellular carcinoma and is involved in cell growth control,” Oncogene, vol. 25, no. 14, pp. 1991–2003, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. G. M. Bol, V. Raman, P. van der Groep et al., “Expression of the RNA helicase DDX3 and the hypoxia response in breast cancer,” PLoS ONE, vol. 8, no. 5, Article ID e63548, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. D.-W. Wu, M.-C. Lee, J. Wang, C.-Y. Chen, Y.-W. Cheng, and H. Lee, “DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer,” Oncogene, vol. 33, no. 12, pp. 1515–1526, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. D.-W. Wu, W.-S. Liu, J. Wang, C.-Y. Chen, Y.-W. Cheng, and H. Lee, “Reduced p21WAF1/CIP1 via alteration of p53-DDX3 pathway is associated with poor relapse-free survival in early-stage human papillomavirus-associated lung cancer,” Clinical Cancer Research, vol. 17, no. 7, pp. 1895–1905, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. C.-H. Lee, S.-H. Lin, S.-F. Yang et al., “Low/negative expression of DDX3 might predict poor prognosis in non-smoker patients with oral cancer,” Oral Diseases, vol. 20, no. 1, pp. 76–83, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. R. H. Hruban, M. B. Pitman, and D. S. Klimstra, Tumors of the Pancreas, vol. 4 of AFIP Atlas of Tumor Pathology, Fascicle 6, American Registry of Pathology—AFIP, Washington, DC, USA, 2007.
  29. W. Wang, Z.-L. Yang, J.-Q. Liu, S. Jiang, and X.-Y. Miao, “Identification of CD146 expression, angiogenesis, and lymphangiogenesis as progression, metastasis, and poor-prognosis related markers for gallbladder adenocarcinoma,” Tumor Biology, vol. 33, no. 1, pp. 173–182, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Lopez, M. Aoubala, F. Jordier, D. Isnardon, S. Gomez, and P. Dubreuil, “The human poliovirus receptor related 2 protein is a new hematopoietic/endothelial homophilic adhesion molecule,” Blood, vol. 92, no. 12, pp. 4602–4611, 1998. View at Google Scholar · View at Scopus
  31. K. Takahashi, H. Nakanishi, M. Miyahara et al., “Nectin/PRR: an immunoglobulin-like cell adhesion molecule recruited to cadherin-based adherens junctions through interaction with Afadin, a PDZ domain-containing protein,” The Journal of Cell Biology, vol. 145, no. 3, pp. 539–549, 1999. View at Publisher · View at Google Scholar
  32. T. Oshima, S. Sato, J. Kato et al., “Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers,” Molecular Cancer, vol. 12, article 60, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. B. Rodamilans and G. Montoya, “Expression, purification, crystallization and preliminary X-ray diffraction analysis of the DDX3 RNA helicase domain,” Acta Crystallographica Section F: Structural Biology and Crystallization Communications, vol. 63, no. 4, pp. 283–286, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Botlagunta, F. Vesuna, Y. Mironchik et al., “Oncogenic role of DDX3 in breast cancer biogenesis,” Oncogene, vol. 27, no. 28, pp. 3912–3922, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. D. R. McGivern and S. M. Lemon, “Tumor suppressors, chromosomal instability, and hepatitis C virus-associated liver cancer,” Annual Review of Pathology: Mechanisms of Disease, vol. 4, pp. 399–415, 2009. View at Publisher · View at Google Scholar · View at Scopus